IceCure Medical (ICCM) Competitors

IceCure Medical logo
$5.40 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$5.47 +0.07 (+1.28%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ICCM vs. NMTC, CTSO, PETV, POAI, and MODD

Should you buy IceCure Medical stock or one of its competitors? MarketBeat compares IceCure Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IceCure Medical include NeuroOne Medical Technologies (NMTC), Cytosorbents (CTSO), PetVivo (PETV), Predictive Oncology (POAI), and Modular Medical (MODD). These companies are all part of the "medical equipment" industry.

How does IceCure Medical compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

NeuroOne Medical Technologies has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

NeuroOne Medical Technologies has a net margin of -68.35% compared to IceCure Medical's net margin of -441.60%. NeuroOne Medical Technologies' return on equity of -99.43% beat IceCure Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-68.35% -99.43% -70.40%
IceCure Medical -441.60%-211.73%-119.13%

NeuroOne Medical Technologies has higher revenue and earnings than IceCure Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$12.10M2.37-$3.61M-$0.85N/A
IceCure Medical$3.57M4.25-$15.06M-$7.21N/A

In the previous week, IceCure Medical had 5 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for IceCure Medical and 1 mentions for NeuroOne Medical Technologies. IceCure Medical's average media sentiment score of 0.35 beat NeuroOne Medical Technologies' score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IceCure Medical
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NeuroOne Medical Technologies presently has a consensus target price of $11.67, indicating a potential upside of 254.61%. IceCure Medical has a consensus target price of $62.70, indicating a potential upside of 1,061.11%. Given IceCure Medical's higher possible upside, analysts clearly believe IceCure Medical is more favorable than NeuroOne Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

NeuroOne Medical Technologies beats IceCure Medical on 9 of the 14 factors compared between the two stocks.

How does IceCure Medical compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Cytosorbents has a net margin of -31.85% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat Cytosorbents' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytosorbents-31.85% -235.57% -37.88%
IceCure Medical -441.60%-211.73%-119.13%

Cytosorbents has higher revenue and earnings than IceCure Medical. Cytosorbents is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytosorbents$37.06M0.74-$8.20M-$0.19N/A
IceCure Medical$3.57M4.25-$15.06M-$7.21N/A

Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

In the previous week, IceCure Medical had 1 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for IceCure Medical and 5 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.98 beat IceCure Medical's score of 0.35 indicating that Cytosorbents is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytosorbents
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IceCure Medical
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,126.33%. IceCure Medical has a consensus price target of $62.70, indicating a potential upside of 1,061.11%. Given Cytosorbents' higher probable upside, analysts clearly believe Cytosorbents is more favorable than IceCure Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytosorbents
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Cytosorbents beats IceCure Medical on 10 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to PetVivo?

PetVivo (NASDAQ:PETV) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

PetVivo has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

IceCure Medical has a net margin of -441.60% compared to PetVivo's net margin of -902.82%. IceCure Medical's return on equity of -211.73% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
PetVivo-902.82% -4,813.07% -281.78%
IceCure Medical -441.60%-211.73%-119.13%

24.5% of PetVivo shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, IceCure Medical had 4 more articles in the media than PetVivo. MarketBeat recorded 6 mentions for IceCure Medical and 2 mentions for PetVivo. IceCure Medical's average media sentiment score of 0.35 beat PetVivo's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PetVivo
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
IceCure Medical
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

PetVivo has higher earnings, but lower revenue than IceCure Medical. PetVivo is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PetVivo$1.05M27.86-$10.95M-$0.38N/A
IceCure Medical$3.57M4.25-$15.06M-$7.21N/A

IceCure Medical has a consensus price target of $62.70, suggesting a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than PetVivo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PetVivo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

IceCure Medical beats PetVivo on 10 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to Predictive Oncology?

IceCure Medical (NASDAQ:ICCM) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

In the previous week, IceCure Medical had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 6 mentions for IceCure Medical and 0 mentions for Predictive Oncology. IceCure Medical's average media sentiment score of 0.35 beat Predictive Oncology's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company Overall Sentiment
IceCure Medical Neutral
Predictive Oncology Neutral

IceCure Medical has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

IceCure Medical currently has a consensus target price of $62.70, indicating a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher probable upside, research analysts clearly believe IceCure Medical is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Predictive Oncology has lower revenue, but higher earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.57M4.25-$15.06M-$7.21N/A
Predictive Oncology$1.66M14.52-$12.66M-$13.50N/A

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IceCure Medical has a net margin of -441.60% compared to Predictive Oncology's net margin of -5,065.23%. IceCure Medical's return on equity of -211.73% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-441.60% -211.73% -119.13%
Predictive Oncology -5,065.23%-732.73%-235.55%

Summary

IceCure Medical beats Predictive Oncology on 11 of the 16 factors compared between the two stocks.

How does IceCure Medical compare to Modular Medical?

IceCure Medical (NASDAQ:ICCM) and Modular Medical (NASDAQ:MODD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

IceCure Medical has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Modular Medical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

In the previous week, IceCure Medical had 6 more articles in the media than Modular Medical. MarketBeat recorded 6 mentions for IceCure Medical and 0 mentions for Modular Medical. IceCure Medical's average media sentiment score of 0.35 beat Modular Medical's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.

Company Overall Sentiment
IceCure Medical Neutral
Modular Medical Neutral

IceCure Medical presently has a consensus price target of $62.70, suggesting a potential upside of 1,061.11%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Modular Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IceCure Medical
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Modular Medical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 7.1% of Modular Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Modular Medical has a net margin of 0.00% compared to IceCure Medical's net margin of -441.60%. IceCure Medical's return on equity of -211.73% beat Modular Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
IceCure Medical-441.60% -211.73% -119.13%
Modular Medical N/A -245.85%-190.80%

IceCure Medical has higher revenue and earnings than Modular Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IceCure Medical$3.57M4.25-$15.06M-$7.21N/A
Modular MedicalN/AN/A-$18.82M-$14.71N/A

Summary

IceCure Medical beats Modular Medical on 11 of the 15 factors compared between the two stocks.

Get IceCure Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ICCM vs. The Competition

MetricIceCure MedicalMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$15.16M$8.76B$6.42B$12.59B
Dividend YieldN/A1.73%2.68%5.81%
P/E Ratio-0.7524.7324.7824.44
Price / Sales4.2522.34553.91122.27
Price / CashN/A102.9745.0755.09
Price / Book1.455.6410.806.58
Net Income-$15.06M$179.69M$3.57B$337.17M
7 Day Performance125.94%1.96%0.72%0.83%
1 Month Performance-23.63%2.99%0.41%2.25%
1 Year Performance-81.08%6.36%29.34%36.14%

IceCure Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ICCM
IceCure Medical
2.9811 of 5 stars
$5.40
flat
$62.70
+1,061.1%
-81.1%$15.16M$3.57MN/A60
NMTC
NeuroOne Medical Technologies
2.4411 of 5 stars
$3.38
-2.5%
$11.67
+245.7%
-16.9%$29.09M$12.10MN/A20
CTSO
Cytosorbents
3.2534 of 5 stars
$0.44
+6.5%
$5.38
+1,118.8%
-62.9%$27.69M$37.20MN/A220
PETV
PetVivo
N/A$0.73
+0.6%
N/A+0.1%$26.74M$1.05MN/A20
POAI
Predictive Oncology
N/A$7.32
-5.3%
N/A-45.4%$24.84M$1.66MN/A30

Related Companies and Tools


This page (NASDAQ:ICCM) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners